Inhibition of matrix metalloproteinase activity in vivo protects against vascular hyporeactivity in endotoxemia

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 298, Issue 1, 2010, Pages

  Cena, Jonathan J ^a   Lalu, Manoj M ^a   Cho, Woo Jung ^a   Chow, Ava K ^a   Bagdan, Mariel L ^a   Daniel, Edwin E ^a   Castro, Michele M ^a   Schulz, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Doxycycline; Endotoxemia; Matrix metalloproteinase; Vascular hyporeactivity

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; DOXYCYCLINE; GELATIN; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE; PHENYLEPHRINE; POTASSIUM CHLORIDE; PYROGEN; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENDOTOXEMIA; ENZYME ACTIVITY; EX VIVO STUDY; EXCISION; HEART CONTRACTION; HOMOGENATE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INJECTION; MALE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTECTION; RAT; SPRAGUE DAWLEY RAT; UPREGULATION; VASCULAR RING; ZYMOGRAPHY;

ANIMALS; AORTA, THORACIC; BLOOD VESSELS; BLOTTING, WESTERN; DOXYCYCLINE; ENDOTOXEMIA; GELATIN; LIPOPOLYSACCHARIDES; MALE; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICROSCOPY, CONFOCAL; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE TYPE II; PHENYLEPHRINE; PROTEASE INHIBITORS; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTOR AGENTS;

EID: 73549087609     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00273.2009     Document Type: Article

References (49)

1. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA 93: 14014-14019, 1996.
2. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 275: 87-90, 1990.
3. Carney DE, McCann UG, Schiller HJ, Gatto LA, Steinberg J, Picone AL, Nieman GF. Metalloproteinase inhibition prevents acute respiratory distress syndrome. J Surg Res 99: 245-252, 2001.
4. Cena J, Lalu MM, Rosenfelt C, Schulz R. Endothelial dependence of matrix metalloproteinase-mediated vascular hyporeactivity caused by lipopolysaccharide. Eur J Pharmacol 582: 116-122, 2008.
5. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101: 1833-1839, 2000.
6. Chew DK, Conte MS, Khalil RA. Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction. J Vasc Surg 40: 1001-1010, 2004.
7. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 152: 189-205, 2007.
8. Crowley SR. The pathogenesis of septic shock. Heart Lung 25: 124-134, 1996.
9. Dubois B, Starckx S, Pagenstecher A, Oord J, Arnold B, Opdenakker G. Gelatinase B deficiency protects against endotoxin shock. Eur J Immunol 32: 2163-2171, 2002.
10. Fleming I, Gray GA, Julou-Schaeffer G, Parratt JR, Stoclet JC. Incubation with endotoxin activates the L-arginine pathway in vascular tissue. Biochem Biophys Res Commun 171: 562-568, 1990.
11. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90: 251-262, 2002.
12. Golub LM, Ciancio S, Ramamamurthy NS, Leung M, McNamara TF. Low-dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans. J Periodontal Res 25: 321-330, 1990.
13. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 12: 12-26, 1998.
14. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93: 178-193, 2001.
15. Hom GJ, Grant SK, Wolfe G, Bach TJ, MacIntyre DE, Hutchinson NI. Lipopolysaccharide-induced hypotension and vascular hyporeactivity in the rat: tissue analysis of nitric oxide synthase mRNA and protein expression in the presence and absence of dexamethasone, NG-monomethyl-L-arginine or indomethacin. J Pharmacol Exp Ther 272: 452-459, 1995.
16. Khadour FH, Panas D, Ferdinandy P, Schulze C, Csont T, Lalu MM, Wildhirt SM, Schulz R. Enhanced NO and superoxide generation in dysfunctional hearts from endotoxemic rats. Am J Physiol Heart Circ Physiol 283: H1108-H1115, 2002.
17. Kishnani NS, Tabrizi-Fard MA, Fung HL. Diethyldithiocarbamate prolongs survival of mice in a lipopolysaccharide-induced endotoxic shock model: evidence for multiple mechanisms. Shock 11: 264-268, 1999.
18. Kivela-Rajamaki M, Maisi P, Srinivas R, Tervahartiala T, Teronen O, Husa V, Salo T, Sorsa T. Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase-2) in diseased human peri-implanted sulcular fluid. J Periodontal Res 38: 583-590, 2003.
19. Kooy NW, Lewis SJ, Royall JA, Ye YZ, Kelly DR, Beckman JS. Extensive tyrosine nitration in human myocardial inflammation: evidence for the presence of peroxynitrite. Crit Care Med 25: 812-819, 1997.
20. Kumar A, Haery C, Parrillo JE. Myocardial dysfunction in septic shock: Part I. Clinical manifestation of cardiovascular dysfunction. J Cardiothorac Vasc Anesth 15: 364-376, 2001.
21. Lalu MM, Cena J, Chowdhury R, Lam A, Schulz R. Matrix metalloproteinases contribute to endotoxin and interleukin-1beta induced vascular dysfunction. Br J Pharmacol 149: 31-42, 2006.
22. Lalu MM, Csont T, Schulz R. Matrix metalloproteinase activities are altered in the heart and plasma during endotoxemia. Crit Care Med 32: 1332-1337, 2004.
23. Lalu MM, Gao CQ, Schulz R. Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: a potential role for MMP-9. Mol Cell Biochem 251: 61-66, 2003.
24. Lehti K, Lohi J, Valtanen H, Keski-Oja J. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem J 334: 345-353, 1998.
25. Liu P, Sun M, Sader S. Matrix metalloproteinases in cardiovascular disease. Can J Cardiol 22: 25B-30B, 2006.
26. Maitra SR, Bhaduri S, Valane PD, Tervahartiala T, Sorsa T, Ramamurthy N. Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis. Shock 20: 280-285, 2003.
27. Marcet-Palacios M, Graham K, Cass C, Befus AD, Mayers I, Radomski MW. Nitric oxide and cyclic GMP increase the expression of matrix metalloproteinase-9 in vascular smooth muscle. J Pharmacol Exp Ther 307: 429-436, 2003.
28. Masure S, Proost P, Van Damme J, Opdenakker G. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur J Biochem 198: 391-398, 1991.
29. Nip LH, Uitto VJ, Golub LM. Inhibition of epithelial cell matrix metalloproteinases by tetracyclines. J Periodontal Res 28: 379-385, 1993.
30. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 276: 29596-29602, 2001.
31. Opdenakker G, Masure S, Grillet B, Van Damme J. Cytokine-mediated regulation of human leukocyte gelatinases and role in arthritis. Lymphokine Cytokine Res 10: 317-324, 1991.
32. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424, 2007.
33. Pagenstecher A, Stalder AK, Campbell IL. RNAse protection assays for the simultaneous and semiquantitative analysis of multiple murine matrix metalloproteinase (MMP) and MMP inhibitor mRNAs. J Immunol Methods 206: 1-9, 1997.
34. Pagenstecher A, Stalder AK, Kincaid CL, Volk B, Campbell IL. Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide-induced endotoxemia in mice. Am J Pathol 157: 197-210, 2000.
35. Pastor CM, Billiar TR. Nitric oxide causes hyporeactivity to phenylephrine in isolated perfused livers from endotoxin-treated rats. Am J Physiol Gastrointest Liver Physiol 268: G177-G182, 1995.
36. Pugin J, Widmer MC, Kossodo S, Liang CM, Preas HLn, Suffredini AF. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 20: 458-464, 1999.
37. Raffetto JD, Ross RL, Khalil RA. Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K+ channels: relevance to varicose vein formation. J Vasc Surg 45: 373-380, 2007.
38. Rees DD, Cellek S, Palmer RM, Moncada S. Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun 173: 541-547, 1990.
39. Sadowski T, Steinmeyer J. Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes. J Rheumatol 28: 336-340, 2001.
40. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 47: 211-242, 2007.
41. Smith GN Jr, Mickler EA, Hasty KA, Brandt KD. Specificity of inhibition of matrix metalloproteinase activity by doxycycline. Arthritis Rheum 42: 1140-1146, 1999.
42. Steinberg J, Halter J, Schiller H, Gatto L, Carney D, Lee HM, Golub L, Nieman G. Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock 24: 348-356, 2005.
43. Szabo C, Cuzzocrea S, Zingarelli B, O'Connor M, Salzman AL. Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J Clin Invest 100: 723-735, 1997.
44. Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6: 662-680, 2007.
45. Szabo C, Salzman AL, Ischiropoulos H. Endotoxin triggers the expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in the rat aorta in vivo. FEBS Lett 363: 235-238, 1995.
46. Szabo C, Zingarelli B, Salzman AL. Role of poly-ADP ribosyltransferase activation in the vascular contractile and energetic failure elicited by exogenous and endogenous nitric oxide and peroxynitrite. Circ Res 78: 1051-1063, 1996.
47. Viappiani S, Nicolescu AC, Holt A, Sawicki G, Crawford BD, Leon H, van Mulligen T, Schulz R. Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol 77: 826-834, 2009.
48. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106: 1543-1549, 2002.
49. Wright RC, Winkelmann RK. The epinephrine response of isolated rabbit vascular strips after in vivo and in vitro endotoxin exposure. Angiology 22: 495-500, 1971.